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ABSTRACT  24 
Bluetongue is a major infectious disease of ruminants caused by bluetongue virus (BTV), an arbovirus 25 
transmitted by Culicoides. Here, we assessed virus and host factors influencing the clinical outcome of 26 
BTV infection using a single experimental framework. We investigated how mammalian host species, 27 
breed, age, BTV serotypes, and strains within a serotype, affect the clinical course of bluetongue. 28 
Results obtained indicate that in small ruminants there is a marked difference in the susceptibility to 29 
clinical disease induced by BTV at the host species level, but less so at the breed level. No major 30 
differences in virulence were found between divergent serotypes (BTV-8 and BTV-2). However, we 31 
observed striking differences in virulence between closely related strains of the same serotype 32 
collected towards the beginning and the end of the European BTV-8 outbreak. As observed previously, 33 
differences in disease severity were also observed when animals were infected with either blood from 34 
a BTV-infected animal or from the same virus isolated in cell culture. Interestingly, with the exception 35 
of two silent mutations, full viral genome sequencing showed identical consensus sequences of the 36 
virus before and after cell culture isolation. However, deep sequencing analysis revealed a marked 37 
decrease in the genetic diversity of the viral population after passaging in mammalian cells. In 38 
contrast, passaging in Culicoides cells increased the overall number of low frequency variants 39 
compared to virus never passaged in cell culture. Thus, Culicoides might be a source of new viral 40 
variants and viral population diversity can be another factor influencing BTV virulence.  41 
 42 
 43 
 44 
 45 
 46 
 47 
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IMPORTANCE 48 
Bluetongue is one of the major infectious diseases of ruminants. It is caused by an arbovirus known as 49 
Bluetongue virus (BTV). The clinical outcome of BTV infection is extremely variable.  We show that 50 
there are clear links between the severity of bluetongue and the mammalian host species infected, 51 
while at the breed level differences were less evident. No differences were observed in the virulence 52 
of two different BTV serotypes (BTV-8 and BTV-2). In contrast, we show that the European BTV-8 strain 53 
isolated at the beginning of the bluetongue outbreak in 2006 was more virulent than a strain isolated 54 
towards the end of the outbreak. In addition, we show that there is a link between the variability of 55 
the BTV population as a whole and virulence and our data also suggest that Culicoides cells might 56 
function as an "incubator" of viral variants.  57 
58 
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INTRODUCTION 59 
Bluetongue is one of the major infectious diseases of ruminants and is caused by bluetongue virus 60 
(BTV), a virus transmitted from infected to uninfected hosts by Culicodes biting midges (1). BTV is the 61 
type species of the genus Orbivirus within the virus family Reoviridae and possesses a genome 62 
consisting of 10 segments of double-stranded RNA (dsRNA) encoding for 7 structural and 4 non-63 
structural proteins (1-3). The icosahedral particle is organized as a triple layer of capsid shells (4, 5). 64 
The outer capsid is formed by VP2 and VP5, while the inner layer is composed of two major proteins, 65 
VP3 (sub core) and VP7 (core), encasing the 10 genomic segments of linear dsRNA and three minor 66 
enzymatic proteins, VP1 (RNA-dependent RNA polymerase), VP4 (RNA capping enzyme) and VP6 (RNA-67 
dependent ATPase and helicase) (2, 4, 5). In addition, BTV expresses four non-structural proteins (NS1, 68 
NS2, NS3 and NS4) involved in virus replication, morphogenesis and in counteracting the innate 69 
immune system of the host (3, 6, 7).  70 
There are at least 26 BTV serotypes (BTV-1 to BTV-26) circulating worldwide. Serotypes are 71 
determined primarily by differences in the outer capsid protein VP2, which induces neutralizing 72 
antibodies in infected animals (8-13).  73 
Bluetongue is enzootic in areas where the mammalian reservoirs, the virus and the insect vector have 74 
the opportunity to coexist in climatic conditions conducive to BTV replication and transmission. As a 75 
result, historically BTV was present exclusively in tropical and subtropical areas of the world where 76 
suitable conditions exist. However, in the last 10-20 years the global distribution of bluetongue,  77 
similarly to some of the other vector borne diseases, has expanded dramatically, potentially due to a 78 
variety of factors including an increased global travel and commerce,  deforestation and climate 79 
change (14-17).   80 
An interesting aspect of bluetongue is the extreme variability of the clinical outcome as a result of BTV 81 
infection. In many cases, BTV induces only mild or inapparent clinical infections, while in others it can 82 
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kill the infected host. Symptoms of Bluetongue have been mainly attributed to the damage of small 83 
blood vessels increasing vascular permeability and resulting in hyperemia, congestion, vascular 84 
thrombosis, localized / diffused edema, hemorrhages and erosion of the mucous membranes. The 85 
main clinical signs of affected animals include fever, depression, respiratory distress and anorexia (18-86 
21).  87 
This variability of clinical outcomes induced by BTV has been attributed to a variety of factors such as 88 
species, breed, age and the immune status of the mammalian host, as well as the serotype/strain of 89 
the virus (21-24). In general, sheep, yak, llamas, and alpacas have been described as the most sensitive 90 
species to BTV–induced disease. Cattle and other wild ruminants have a certain degree of resistance to 91 
disease, although they are fully susceptible to infection. Cattle show longer periods of viremia and are, 92 
therefore, considered reservoirs of infection (21, 25-31). Goats are also susceptible to BTV infection 93 
but do not appear to be very susceptible to disease, although contrasting reports appear in the 94 
literature and the heterogeneous experimental conditions used in different studies make it difficult to 95 
compare the available data (19, 24, 32-36).  96 
The immunologic status of infected animals understandably has a major influence on the susceptibility 97 
to infection and explains why outbreaks of bluetongue typically occur when susceptible animal species 98 
are introduced into endemic areas, or when virulent strains of BTV reach previously unexposed 99 
ruminant populations (21). Animals infected with a specific BTV serotype produce long lasting 100 
neutralizing antibodies with limited cross protection against heterologous serotypes (37). 101 
Environmental factors, such as the exposure to solar radiation or high temperatures, can also 102 
exacerbate the disease symptoms (38, 39). 103 
While infection of sheep in the tropics and subtropics is common, clinical disease in indigenous breeds 104 
is rarely observed. The North European breeds of sheep have been described to be very susceptible to 105 
BTV-induced disease as opposed to African or South-East Asian breeds (19, 22, 40-47). Within the 106 
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same sheep breed, or even within the same flock, there may be considerable differences in the 107 
severity of the disease occurrence in individual animals (21, 23).  108 
Serotypes/strains of BTV with different degrees of virulence have been described in the literature. For 109 
example, the North European BTV-8 strains that spread since 2006 in Northern Europe is considered  110 
highly virulent as it induced high levels of mortality in naïve sheep and in some cases also caused 111 
severe clinical disease in cattle (48-51). On the other hand, it is interesting to note that no clinical 112 
cases of disease were observed even in sheep when BTV-8 reached Northern Italy and Sardinia a few 113 
years later (G. Savini, personal communication). Other serotypes related to vaccine strains (BTV-6, 114 
BTV-11, BTV-14) have entered Europe briefly, in general showing very little pathogenicity in the field 115 
(52-54).  116 
Bluetongue is experimentally reproducible and several studies have addressed, directly or indirectly, 117 
the variability of the clinical outcome resulting from BTV infection, although at times with 118 
contradictory results (55, 56). The heterogeneous experimental conditions used in different studies 119 
make it difficult at times to compare the available data. For example, many of the BTV strains used in 120 
experimental studies have been passaged more or less extensively in cell culture and this can 121 
potentially lead to attenuation of virulence (57, 58). In addition, some reports in the literature stress 122 
that experimental infection using BTV strains isolated in mammalian cell cultures from lethal cases of 123 
bluetongue most often results only in the induction of mild clinical signs of the disease (39, 59, 60). 124 
Thus, some investigators have used blood from viremic animals as an inoculum and this appeared to 125 
be a very effective way to induce severe clinical signs in the infected animals (20, 61). However, the 126 
induction of severe clinical signs of bluetongue have also been reported using BTV passaged in cell 127 
culture (62) or virus isolated in embryonated eggs (32, 40).  128 
Here, we used a single experimental framework and standardised conditions in order to systematically 129 
assess virus and host factors influencing the clinical outcome of BTV infection. We evaluated 130 
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differences in susceptibility to BTV-induced disease in goats, and sheep of different breeds. In addition, 131 
we studied differences in the virulence of two divergent BTV serotypes (BTV-2 and BTV-8), as well as 132 
the virulence of different BTV-8 strains isolated at the beginning and end of the North European 133 
outbreak of 2006-2008. Finally, we evaluated whether genetic bottlenecks (63) exist that can influence 134 
BTV adaptation in Culicoides and mammalian cells and also how these influence virulence.    135 
136 
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MATERIAL AND METHODS 137 
Cells. Mammalian cells were grown at 37°C in a humidified atmosphere supplemented with 5% CO2. 138 
BHK-21, BSR (a clone of BHK-21 cells ), and African green monkey VERO cells were grown in Dulbecco’s 139 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). CPT-Tert cells are 140 
sheep choroid plexus cells immortalized with the simian virus 40 (SV40) T antigen and human 141 
telomerase reverse transcriptase (hTERT) and were grown at 37°C in Iscove’s modified Dulbecco’s 142 
medium (IMDM), supplemented with 10% FBS (64). KC cells (65) were derived from Culicoides 143 
sonorensis larvae and grown at 28°C in Schneider’s insect medium supplemented with 10% FBS. 144 
Virus strains and titrations. BTV-8NET2006 (Pirbright reference collection number NET2006/04) was 145 
originally isolated from a naturally infected sheep during the 2006 outbreak in Northern Europe and 146 
has been previously described (3). BTV-8NET2007(blood) was derived from the spleen of a sheep infected 147 
with blood derived from a naturally infected cow in the Netherland during the 2007 BTV-8 outbreak as 148 
already described (66). Further viruses were isolated in vitro from BTV-8NET2007(blood) after (i) 1 passage 149 
in KC cells (BTV-8 NET2007(1KC)), (ii) 1 passage in KC and 1 passage in BHK21 cells (BTV-8 NET2007(1KC/1BHK)) and 150 
(iii) 1 passage in KC and 2 passages in BHK21 cells (BTV-8 NET2007(1KC/2BHK)).  151 
BTV-2IT2000 and BTV-8IT2008 were derived from naturally occurring outbreaks of bluetongue in sheep in 152 
Italy and were isolated in 2000 and 2008 respectively. All viruses used in this study were isolated in KC 153 
cells and subsequently passaged twice in BHK-21 cells before use in experimental infections. Virus 154 
stocks were prepared by infecting BHK-21 cells at a multiplicity of infection (MOI) of 0.01 and 155 
collecting the supernatant when obvious cytopathic effect (CPE) was observed. Supernatants were 156 
clarified by centrifugation at 500 g for 5 min and the resulting virus suspensions aliquoted and stored 157 
at 4°C. Virus titers were determined by standard plaque assays (67). In order to compare the growth of 158 
the various BTVs strains used in this study, CPT-Tert cells were infected at a multiplicity of infection 159 
(MOI) of 0.01 and supernatants collected at 8, 24, 48, 72 and 96h post infection (p.i.). Samples from 160 
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each time point were subsequently titrated by endpoint dilution analysis in BSR cells, and titers were 161 
expressed as 50% tissue culture infective doses (TCID50). Each assay was repeated at least twice using 162 
two different virus stocks. 163 
BTV genome sequencing. The complete genome sequences were derived from the following strains: 164 
BTV-8IT2008, BTV-8NET2007(blood), BTV-8 NET2007(1KC), BTV-8 NET2007(1KC/1BHK) and BTV-8NET2007(1KC/2BHK). dsRNA 165 
was extracted from the spleen or infected cells as previously described (57). Full length genome 166 
segments were amplified from dsRNA using SuperScript® III One-Step RT-PCR System with Platinum® 167 
Taq DNA Polymerase (Invitrogen) using primers complementary to the 5’ or 3’ end termini of the viral 168 
genome segments. The genome of BTV-8IT2008 was sequenced using the Sanger method. For the other 169 
viruses, equimolar, purified PCR products of the 10 genomic segments of each virus were pooled, 170 
sheared by focused sonication (Covaris), followed by size selection using Ampure XP magnetic beads. 171 
Illumina MiSeq libraries were generated using the KAPA real-time Library preparation kit (KAPA),  172 
further quantified using qRT-PCR (KAPA) and sequenced using an Illumina MiSeq with a 300 cycle 173 
cartridge as suggested by the manufacturers. Analysis of genetic diversity was carried out using CLC 174 
Genomic Workbench Version 6.0.1 (CLC bio).  After quality assessment and the removal of sequencing 175 
artefacts, reads were mapped using BTV-8NET2006 as a reference sequence and the consensus 176 
sequences extracted. Reads with a similarity fraction below 70% were omitted in the final assembly. 177 
Single nucleotide polymorphisms were identified using the quality based variant detection function 178 
within CLC Genomics Workbench Version 6.0.1. Total sample reads were mapped to the consensus 179 
sequence of each segment and variants were called using as parameters nucleotides with total 180 
coverage of over 100 reads and central quality score of Q20 or higher. Average quality score per 181 
nucleotide was above Q35.8 in all samples. The mean depth of coverage per variant in each viral 182 
genome was between 8154 and 12461. Presence of both forward and reverse read were required to 183 
call a variant while the frequency threshold was arbitrarily set at 0.1%.   184 
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Nucleotide sequence accession numbers. Sequences of BTV-2IT2000 and BTV-8IT2008 have been deposited 185 
in GenBank and were assigned accession numbers KM053268 to KM053277 (BTV-2IT2000) and 186 
KM053258 to KM053267 (BTV-8IT2008). The raw data used for deep-sequencing analyses are available 187 
upon request.  188 
Experimental infections in mice. Transgenic mice deficient in type I interferon (IFN) receptor (129sv 189 
IFNAR-/-; B&K Universal Ltd.) were maintained at biosafety level 3. For each experiment, groups of adult 190 
mice matched for sex and age (n=5 per group), were infected intraperitoneally with 300 PFU of virus or 191 
mock-infected as indicated in the Results section. Mice were examined for clinical symptoms daily until 192 
the experiment was concluded at 14 days post infection.  193 
In vivo pathogenicity studies. Animal experiments were carried out at the Istituto Zooprofilattico 194 
Sperimentale dell’Abruzzo e Molise “G. Caporale” (Teramo, Italy) in accordance with local and national 195 
approved protocols regulating animal experimental use (protocol n. 10933/2011 and 7440/2012).  196 
Studies were conducted using a total of 65 sheep and 10 goats held in an insect-proof isolation unit 197 
with veterinary care. All animals were confirmed to lack antibodies towards BTV using a BTV blocking 198 
ELISA as previously described (68). The absence of BTV-specific antibodies was confirmed for each 199 
animal using a BTV-specific qRT-PCR in blood samples (see below).  For this study, all animals were 200 
infected intradermally with a total of 2X106 PFU (in 5 ml) of the specific BTV strains indicated below by 201 
multiple inoculations in the inner leg and in the pre-scapular areas. Negative controls were inoculated 202 
with 5ml of mock-infected cell-supernatant. Groups (n=5 animals per each group) of domestic goats, 8 203 
months old Dorset, and two years old Sardinian, Dorset and Italian mixed breed sheep were infected 204 
with BTV-8NET2006. Two additional groups of Sardinian sheep were inoculated with BTV-8IT2008
 or BTV-205 
2IT2000. Two additional groups of Sardinian sheep (n=5 per group) were inoculated with either 5ml of 206 
infected blood (BTV-8NET2007(blood)) or with the same virus after passage in KC and BHK21 cells (BTV-207 
8NET2007(1KC-2BHK)). All viruses used in this study have the same passage history (1 passage in KC cells and 208 
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two passages in BHK21 cells) unless indicated otherwise. 5 goats and 25 sheep (5 adult Dorset, 5 young 209 
Dorset, 5 Italian mixed breed and 10 Sardinian sheep) were used as negative controls and were 210 
inoculated with uninfected cell culture media. Blood samples were collected (with EDTA) from all 211 
infected animals, daily for 15 days post-infection and thereafter at day 17, 19, 21 and 28 p.i. when the 212 
experiment was concluded. The blood samples were analyzed for the presence of viremia by qRT-PCR 213 
(see below). Serum samples were collected from each animal on the day of the inoculation (day 0) and 214 
then at day 7, 14, 21 and 28 p.i.  Sera were tested by virus neutralization assay for the presence of BTV-215 
specific antibodies. Body temperature and clinical signs were recorded daily, beginning a week before 216 
inoculation, until day 15 p.i. and subsequently at day 17, 19, 21 and 28 pi. Fever was defined as rectal 217 
temperature above 40°C. Clinical signs were scored using a clinical reaction index (CRI) with minor 218 
modifications as already described (66) (Table S1).  219 
Virus neutralization assays. The presence of neutralizing antibodies in infected sheep and goats, 220 
against the BTV strains used was assessed by neutralization assays testing serial 2-fold dilutions of sera 221 
as already described (69).  Briefly, serum dilutions (1:10 to 1:1,280) and a fixed amount of virus (100 222 
TCID50) were incubated for 1h at 37°C in 96 well  plates, whereupon 100 μl suspension of VERO cells 223 
(3×105/ml) was added to each well in minimum essentials medium (MEM). Plates were incubated for 224 
6–7 days at 37°C, 5% CO2 after which monolayers were then scored for cytopathic effect (CPE). The 225 
titer of neutralizing antibodies in each serum sample was determined by endpoint dilution assays (70). 226 
Values reported for each sample are the log10 of the 50% endpoint (proportionate distance, PD) of 4 227 
replicates performed using VERO cells. 228 
qRT-PCR. Viremia in experimentally infected animals was assessed by qRT-PCR as already described 229 
(57, 69). Briefly, blood samples (500 μl) were pre-treated with 1 ml cold distilled water on ice for 10 230 
min and then centrifuged at 4°C for 10 min at 13000 g. Armored RNA (Asuragen, USA) was added to 231 
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each sample before RNA extraction and used as an internal control to verify RNA extraction efficiency. 232 
Total RNA was extracted from the resulting cellular pellet, using the High Pure Nucleic Acid extraction 233 
kit (Roche, Nutley, New Jersey), in accordance with the manufacturer’s instructions. The quality of the 234 
samples was further assessed by amplifying the sheep β-actin gene as previously described (71). For 235 
each sample, 250 ng of RNA was used in a one-step qRT-PCR reaction employing primers/probes for 236 
segment 5 (encoding NS1) of BTV and the armored control RNA. Samples were analysed using a 7900HT 237 
fast real-time PCR system and the sequence detection system software SDS, version 2.3 (Applied 238 
Biosystems). BTV genome copy numbers expressed as log10/µg of total RNA were derived using a 239 
standard curve generated from the amplification of in vitro transcribed synthetic BTV segment 5 RNA 240 
using the mMESSAGE mMACHINE T7 Ultra Kit (Ambion), according to the manufacturer’s instructions. 241 
Signal levels with CT values ≥ 40 were considered negative.  242 
Statistical analysis. Statistical analysis was carried out using the software Prism (GraphPad). 243 
Significance of differences in body temperature between groups of infected animals was estimated by 244 
calculating the total area under the curve (AUC) of body temperatures between days 3 to 11 p.i. for 245 
each animal. Significant differences between groups were calculated using an unpaired t test or 246 
ANOVA as appropriate. The AUC relative to the levels of BTV RNA in the blood was calculated for each 247 
animal from day 1 p.i. to the end of the experiment and groups were compared using an unpaired t 248 
test or ANOVA as appropriate. In addition, significant differences in the peak levels of viremia were 249 
also compared using an unpaired t test or ANOVA as appropriate.   250 
251 
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RESULTS 252 
Replication kinetics in vitro and virulence in mice of BTV-2IT2000, BTV-8NET2006 and BTV-8IT2008. In order 253 
to investigate virus and host factors affecting the clinical outcome of BTV infection we initially focused 254 
on three different strains of bluetongue: a BTV-2 strain isolated from Italy in 2000 (BTV-2IT2000), a BTV-8 255 
strain isolated from the Netherlands in 2006 (BTV-8NET2006) and a BTV-8 strain isolated in Italy in 2008 256 
(BTV-8IT2008).  257 
Firstly, we assessed the ability of all viruses to replicate in sheep CPT-Tert cells. No major differences 258 
were observed in the replication kinetics of the viruses regardless of the serotype and strain used in 259 
the assay (Fig. 1A). We next assessed the virulence of each strain in IFNAR-/- mice as these mice 260 
succumb to wild type BTV infection (57, 72).  Mice were inoculated intraperitoneally with 300 PFU of 261 
the BTV strains above. All of the mice inoculated with the various BTV strains showed clinical signs 262 
around 3 days p.i. characterized by ocular discharge, apathy and lethargy. All BTV infected mice died 263 
between 6 and 8 days post-infection while no signs of disease were observed in the control mock-264 
infected mice (Fig. 1B). 265 
Influence of species, breed and age of the mammalian host on the clinical outcome of BTV infection. 266 
Several studies investigating the factors that affect the clinical outcome to BTV infection have already 267 
been published (1, 20, 21, 73). Here, we aimed to assess the variables affecting the pathogenesis of 268 
bluetongue in a single experimental framework. First, we assessed the outcome to BTV infection in 2 269 
year-old goats and sheep of three different breeds (the Northern European Dorset Poll, the Italian 270 
Sardinian sheep and a mixed breed from Central Italy). An additional group of Dorset poll sheep, 8 271 
months old in age, were also used in the study. We deliberately used viruses isolated in KC cells and 272 
subsequently passaged twice in BHK-21 for all the experimental infections carried out in this study. 273 
This strategy allowed us to use viruses minimally passaged in vitro and with the same history in cell 274 
culture.   275 
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Sheep infected with BTV-8NET2006 developed classic clinical signs of bluetongue including fever (defined 276 
here as body temperature > 40°C), which started 4-5 days p.i., depression, anorexia, respiratory 277 
distress, increase in salivation, facial edema and hyperaemia of nasal and buccal mucosa (Fig. 2 and 278 
Supplementary Fig. S1, showing data for each individual animal). Overall, no major differences in 279 
clinical signs were observed between the three sheep breeds used in this study nor between 8 month 280 
old and 2 year old Dorset poll sheep. In addition, no significant differences (p > 0.05) were observed in 281 
the levels of fever or the cumulative number of days with fever between all the sheep groups. 282 
However, one sheep in the mixed breed infected group had to be euthanized because of onset of 283 
severe clinical signs. Consequently, the general and total clinical score of the infected mixed breed 284 
group was higher than the other groups (Fig. 2A). In all the infected groups, BTV RNA in the blood 285 
peaked at about 5 days p.i. then slowly decreased, although it remained detectable up to 4 weeks p.i. 286 
at which point the experiment was concluded (Fig. 2C and Supplementary Fig. S1). Neutralizing 287 
antibodies were detected at day 7 p.i., peaked by 14 days p.i. and then remained essentially constant 288 
for the duration of the experiment (Fig. 2D).  289 
On the other hand, goats after BTV-8NET2006 infection showed no clinical signs nor fever throughout the 290 
duration of the experiment (28 days) (Fig. 2A-B). Differences in the body temperature between day 3 291 
and 10 post-infection were statistically significant between goats and each of the groups of sheep used 292 
above (p< 0.0001). The onset of viremia in goats was delayed, compared to infected sheep, peaking at 293 
10 days post-infection. Average levels of BTV RNA in the blood were at least 10 fold higher in goats, 294 
compared to infected sheep, between day 9 and 16 p.i. but overall the differences observed were not 295 
statistically significant due to individual variations (ANOVA p= 0.45) (Fig. 2C and Supplementary Fig. 296 
S1). All mock-infected sheep and goat controls used in this study showed no clinical signs, and 297 
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remained negative for the presence of both viral RNA in the blood and neutralizing antibodies towards 298 
BTV (Fig. S2). 299 
Influence of BTV strain and serotype on the clinical outcome of BTV infection. We also assessed the 300 
pathogenicity of different BTV serotypes, as well as different virus strains within a single serotype. The 301 
severity of disease observed in sheep inoculated with either BTV-2IT2000 or BTV-8NET2006 was largely 302 
equivalent, with both viruses inducing typical clinical signs observed in bluetongue (Fig. 3A). In 303 
contrast, animals infected with BTV-8IT2008 showed only a mild transitory fever but no other clinical 304 
signs (Figs. 3B and Supplementary Fig. S3 showing data for each individual animal). Excluding the 305 
temporary pyrexia displayed by some animals at day 1 p.i., BTV-8NET2006 and BTV-2IT2000 induced 306 
cumulatively 17 and 18 days of fever in their respective groups of infected sheep. In contrast, BTV-307 
8IT2008 induced only 8 cumulative days of fever. Overall, we also observed that on average sheep 308 
infected with BTV-8NET2006 or BTV-2IT2000 displayed higher levels of fever compared to sheep infected 309 
with BTV-8IT2008, although differences were not statistically significant (ANOVA p= 0.17).  BTV-8IT2008, 310 
BTV-8NET2006 and BTV-2IT2000 all induced similar levels of viremia (ANOVA p= 0.54) and neutralizing 311 
antibodies in infected sheep (Fig. 3C-D).  312 
We next sequenced the complete genomes of BTV-8NET2006 and BTV-8IT2008 in order to determine the 313 
genetic basis for the different phenotypes of these two viruses. We detected a total of 24 nucleotide 314 
mutations between BTV-8NET2006 and BTV-8IT2008, including 16 silent mutations and 8 non-synonymous 315 
mutations leading to differences in the viral VP1, VP2, VP4, NS1, NS2 and VP6 proteins (Fig. 4).   316 
Effect of cell culture adaptation on BTV virulence. Published reports suggest that, in some cases, 317 
infection of target species using blood directly from a naturally BTV infected animal induces more 318 
severe clinical signs than tissue culture adapted virus (20, 61). In the context of the experimental 319 
framework used in this study, we inoculated two groups of Sardinian sheep with either blood from a 320 
BTV - infected animal (BTV-8NET2007(blood)), or the same virus isolated in cell culture after a single 321 
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passage in KC cells and two passages in BHK21 (BTV-8NET2007(1KC-2BHK)). As assessed by qRT-PCR, the 322 
infected blood contained approximately 100 fold less viral RNA than the inoculum of BTV-8NET2007(1KC-323 
2BHK) (data not shown). Sheep infected with BTV-8NET2007(blood) displayed a higher clinical score and 324 
reached statistically significant higher levels of fever (p=0.01) compared to sheep inoculated with BTV-325 
8NET2007(1KC-2BHK) (Figs. 5A-B and Supplementary Fig. S4). Sheep infected with BTV-8NET2007(blood) displayed 326 
27 cumulative days of fever as opposed to 16 shown by sheep infected with BTV-8NET2007(1KC-2BHK). In 327 
addition, the levels of viral RNA in the blood were also consistently and considerably higher (10 to 328 
1000 fold; p=0.018) in sheep infected with BTV-8NET2007(blood) compared to those found in BTV-329 
8NET2007(1KC-2BHK) infected sheep (Figs. 5C and Supplementary Fig. S4). Interestingly, viremia was delayed 330 
by 2 days in BTV-8NET2007(blood) infected animals. In addition, we did not find neutralizing antibodies at 7 331 
days post-infection in any of the sheep infected with BTV-8NET2007(blood) (Fig. 5D). In contrast, all sheep 332 
infected with BTV-8NET2007(1KC-2BHK) had BTV neutralizing antibodies by day 7 p.i. No differences in the 333 
levels of neutralizing antibodies were found at later time points between sheep infected with BTV-334 
8NET2007(blood) and  BTV-8NET2007(1KC-2BHK).  Thus, as proposed in other studies (20, 61), infection of sheep 335 
with BTV collected directly from infected animals and never passaged in tissue culture induced more 336 
severe clinical signs than the homologous virus passaged even minimally in tissue culture.  337 
BTV population diversity influences virulence. Next, we aimed to link the phenotypic differences 338 
observed above between sheep inoculated with BTV-8NET2007(blood) or BTV-8NET2007(1KC-2BHK) to genetic 339 
changes that might occur in the virus following cell culture adaptation. We analysed the genomes of 340 
BTV-8NET2007(blood) and BTV-8NET2007(1KC-2BHK) by deep sequencing, using the same stocks utilised in the 341 
experimental infections described above. We also analysed the intermediate viruses BTV-8NET2007(1KC) 342 
and BTV-8NET2007(1KC-1BHK). Furthermore, in order to test the reproducibility of the results obtained, we 343 
repeated in parallel the adaptation in KC and BHK21 cells of BTV-8NET2007(blood) in an independent set of 344 
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experiments. Altogether, we analysed the full genome of 7 viral samples: BTV-8NET2007(blood), and two 345 
independent isolates of BTV-8NET2007(1KC), BTV-8NET2007(1KC-1BHK) and BTV-8NET2007(1KC-2BHK). 346 
We found that the consensus sequences of BTV-8NET2007(blood) and BTV-8NET2007(1KC-2BHK) were identical 347 
with the exception of two silent mutations in segments 1 (nt 2756) and segment 4 (nt 1431) (Fig. 6). 348 
Both point mutations were selected after the initial passage in KC cells and in both independent 349 
experiments.  350 
RNA viruses, due to their high mutation rates, do not exist as a single genotype but as a complex of 351 
variants (also referred to as quasispecies), each possessing unique random mutations (74, 75). 352 
Consequently, we analysed BTV-8NET2007(blood) and the effect on its population diversity after passaging 353 
in vitro in KC and BHK21 cells.  354 
In Fig. 7 we have plotted the degree of variability at each nucleotide position of each genomic segment 355 
before and after passaging in cell culture.  A nucleotide is plotted, and is referred to as a “variant”, if it 356 
represents at least 0.1% of the viral population.  In general, the number of variants was higher in the 357 
virus before cell passaging, or after one passage in KC cells, compared to what observed even after a 358 
single passage in BHK21 cells. Interestingly, for 9 of the 10 segments in the first set of experiments, and 359 
for 8 of the 10 segments in the second set of experiments, the number of variable nucleotides was 360 
higher in the virus passaged once in KC cells as compared to the virus from blood before passage in 361 
cell-culture. There was a larger number of variants with a frequency between 0.1 and 0.29% in BTV-362 
8NET2007(1KC), while the number of variants with a frequency > 0.4% was several fold higher in BTV-363 
8NET2007(blood) (Fig. 8). The two silent mutations selected in the consensus sequence of BTV-8NET2007(1KC-364 
2BHK) were already present as high prevalence variants in BTV-8NET2007(blood) (14.9% for nt 2756 of 365 
segment 1 and 10.4% for nt 1431 of segment 4) (dots circled in red in Fig. 7). On the other hand, other 366 
variants present with a frequency of about 10% in segment 3 and segment 6 were not selected after 367 
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passage in vitro. Essentially, the same results were obtained in the two independent sets of 368 
experiments.  369 
 370 
 371 
372 
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DISCUSSION 373 
Most infections of susceptible hosts by pathogenic viruses result in clinical manifestations that can 374 
vary greatly in their severity. For some viruses, such as avian influenza virus for example, low and 375 
highly virulent strains are distinguishable by clear genotypic differences (76). Nevertheless, in some 376 
circumstances, even infection of susceptible hosts with highly pathogenic viruses can result in mild or 377 
unapparent clinical symptoms.  378 
Bluetongue is a disease characterised by a highly variable clinical spectrum (21-24). Understanding the 379 
basis for this variability is complicated by the fact that BTV exists in nature as many diverse strains 380 
representing different serotypes, topotypes and reassortant viruses often co-circulating in the same 381 
geographical area. In addition, BTV can infect a variety of ruminant species, each with different genetic 382 
and immunological backgrounds. Furthermore, BTV is transmitted by different species of Culicoides in 383 
diverse ecological contexts. There have been several studies concerning naturally occurring 384 
bluetongue or experimentally induced disease, clearly indicating that factors related to both the 385 
mammalian host and the virus can influence the outcome of BTV infection (55). However, it is not 386 
always straightforward to compare data from different studies. Thus, the weight given to different 387 
host or virus factors in determining the clinical outcome to BTV infection can differ in heterogeneous 388 
ecological or experimental settings.   389 
In this study, we dissected both host and virus factors that can affect the clinical outcome of BTV 390 
infection.  The use of a uniform experimental framework has allowed us to rigorously interrogate both 391 
experimental questions addressed in past studies (55), as well as explore hitherto unanswered 392 
questions. First of all, as suggested previously (24, 32-36), we confirmed that while both sheep and 393 
goats are fully susceptible to BTV (in this case BTV-8) infection, the former are more susceptible than 394 
goats and more likely to develop clinical disease. The levels of viremia in BTV-infected goats were not 395 
different (if anything higher) compared to those observed in infected sheep. These data confirm that 396 
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BTV is able to replicate to high levels in goat tissues but cellular damage, either induced by the virus or 397 
the host immune responses, does not likely occur. We do not know if goats would be more susceptible 398 
to disease if we had used higher infectious doses. We have used 2X106 PFU of BTV in our experimental 399 
infections and this is likely far more infectious virus than is transmitted in nature by infected midges. In 400 
addition, studies in sheep using as little as 101.4 TCID50 were able to induce infection in this animal 401 
species  (66).   In two previous studies, also using BTV-8 isolates from the Netherlands, some of the 402 
experimentally infected goats developed mild clinical signs, fever and viremia (34, 36). However, in 403 
both studies, goats were infected intravenously (34, 36) and in one of them animals were infected at 404 
day 62 of gestation (36). Another study used BTV-4 which was isolated in embryonated chicken eggs 405 
and passaged seven times in BHK21. Only 1 of 11 goats (of two different breeds) infected with this virus 406 
showed transient pyrexia, but at the same time 10 of 12 inoculated sheep did not show fever or signs 407 
of disease either (32). Thus, this study confirmed that the mammalian host species is certainly one of 408 
the main factors that determine the clinical outcome to BTV infection. 409 
We did not find major differences in the susceptibility of sheep breeds from the Mediterranean area 410 
(Sardinian and Italian mixed breed) and Northern European breeds (Dorset poll) to bluetongue, 411 
despite their distinct geographical, historical and breeding backgrounds (47). Thus, variations in the 412 
susceptibility to bluetongue of different sheep breeds might not be as pronounced as originally 413 
thought. It is also important to stress that bluetongue itself was first discovered in European breeds 414 
imported into South Africa (77). Those breeds showed a higher susceptibility to bluetongue than local 415 
animals, although the influence of herd immunity on the latter could have also played a role. It is 416 
therefore difficult to weigh the influences of the host's genetic background, previous BTV exposure or 417 
the insect vector on the susceptibility to the disease in that particular context.  418 
We have also analysed the influence of divergent viral serotypes, and closely related but distinct 419 
strains within the same serotype, on the clinical outcome of bluetongue. BTV-8NET2006
 is considered to 420 
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be a highly pathogenic virus (both in terms of morbidity and mortality) and the cause of one of the 421 
largest outbreaks of bluetongue in history (48-51). However, in our experimental setting, we did not 422 
find any difference in virulence between BTV-8NET2006
 and another serotype such as BTV-2IT2000 which 423 
was isolated in Italy in the year 2000 from a naturally occurring case of bluetongue in sheep. Another 424 
study, comparing the virulence of BTV-1 isolated from Algeria and a 2006 isolate of BTV-8 from 425 
Belgium concluded that the former was more virulent than the latter (78). Although in that particular 426 
study, the cell culture passage history was not described and viruses were inoculated sub-cutaneously, 427 
it appears that the overall data suggest that in itself BTV-8NET2006 is not necessarily more virulent than 428 
other BTV serotypes, such as BTV-2 or BTV-1, that have been circulating in Europe in the last decade. It 429 
is likely that other factors, such as the rapid spread of the infection to an extremely large number of 430 
fully susceptible and naïve hosts (never previously exposed even to heterologous BTV serotypes) 431 
contributed to the  number of severe cases of disease observed during the Northern European 432 
outbreak caused by this strain of BTV.  433 
The BTV-8NET2006 strain was isolated from samples collected at the beginning of the European outbreak 434 
of this virus. Since the original cases identified in 2006 in central Europe, BTV-8 moved in subsequent 435 
years towards several surrounding geographical areas (including southwards). Interestingly, in 436 
Northern Italy and in Sardinia, BTV-8 (termed in this study BTV-8IT2008) was only detected at the 437 
serological level in a few animals but it was not associated with clinical disease (G. Savini, personal 438 
communication). We showed conclusively in our study that BTV-8IT2008 was less virulent than BTV-439 
8NET2006. BTV-8IT2008 accumulated several non-synonymous mutations in structural and non-structural 440 
proteins (including VP1, VP2, NS1 and NS2) already implicated in attenuation of tissue culture adapted 441 
BTV-2, BTV-4 and BTV-9 (57). Thus, this study formally proves the appearance of less virulent strains 442 
during a BTV outbreak. The comparative smaller number of severe cases of bluetongue in endemic 443 
areas might depend upon several factors, including the levels of herd immunity, the decrease in 444 
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virulence of circulating BTV strains, and possibly, on the long term selection of genetically resistant 445 
individual animals.  446 
Finally, we further investigated the observation that experimental infection of sheep with blood 447 
collected from naturally occurring cases of bluetongue appears to induces, in general, more severe 448 
clinical cases compared to the disease induced in sheep infected with viruses isolated in tissue culture 449 
or embryonated eggs (20, 61). Indeed, we have confirmed in our experimental framework that sheep 450 
inoculated with BTV-8NET2007(blood) displayed a more severe disease and higher levels of viremia than 451 
those infected with the virus isolated in cell culture (BTV-8NET2007(1KC/2BHK)). It is unlikely that factors 452 
present in the infected blood could be the cause of more severe clinical signs in sheep. Importantly, 453 
the highest levels of fever and the most severe clinical signs in sheep infected with BTV-8NET2007(blood) 454 
were observed between Day 6 and 11 p.i. when the levels of BTV in the blood where at their highest.  455 
Virus passaging in tissue culture can lead to adaptive changes in the viral genotype that could in turn 456 
affect viral virulence. However, we found only 2 synonymous mutations between the consensus 457 
sequence of BTV-8NET2007(blood) and the cell culture isolated virus BTV-8NET2007(1KC-2BHK). Both mutations 458 
were present in approximately 10% of the variants of BTV-8NET2007(blood) and interestingly they were 459 
both selected in two independent experiments. It is possible that these silent mutations in some way 460 
affect viral virulence. In addition, the sequencing methods used did not cover the non-coding regions 461 
of each segment and therefore we may have also missed other important mutations.  However, 462 
overall there appears to be very little (or no variation at all) at the consensus sequence level (at least 463 
for BTV-8) of viruses isolated from blood or minimally passaged in cell culture. RNA viruses have the 464 
highest error rates (10-4-10-6 per nucleotide site per genome replication) of any microorganism due to 465 
their RNA-dependent RNA polymerase lacking proofreading activity during RNA synthesis (79, 80). As 466 
such, RNA viruses exist as a population of variants, genetically closely related but distinct from their 467 
consensus sequence. It is rational to argue that the opportunity to quickly adapt and generate diverse 468 
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viral populations is critical for the survival of RNA viruses (74) in the face of selective pressures, 469 
including the innate and adaptive antiviral responses of the host. For example, polioviruses mutants 470 
with a high fidelity polymerase (and thus low population diversity) display an attenuated phenotype in 471 
mice, despite possessing identical consensus sequences to the virulent wild type viruses (81-83).  472 
We found that BTV-8NET2007(blood) contained the largest number of high frequency variants. However, 473 
when BTV-8NET2007(blood) was passaged in insect KC cells the resulting viral population (BTV-8NET2007(1KC)) 474 
showed the overall highest number of variants, even higher (~ 60%) than those in the blood before 475 
tissue culture isolation. A severe genetic bottleneck was observed after viral passaging in mammalian 476 
BHK21 cells with the resulting viruses (BTV-8NET2007(1KC/1BHK) and BTV-8NET2007(1KC/2BHK)) showing the 477 
smallest degree of variability.  478 
These data suggest that BTV virulence is not only affected by changes in the viral proteins selected at 479 
the consensus level, but also by the genetic variability of the population as a whole. This hypothesis is 480 
also supported by previous observations made in a limited number of genes before the advent of 481 
deep-sequencing (84, 85). In a study that analysed segment 2 of a virulent strain of BTV-1, Gould and 482 
Eaton (84) showed that the consensus sequence did not change after a single passage in tissue culture 483 
that resulted in viral attenuation. In addition, Bonneau and colleagues (85) showed that the number of 484 
variants observed in segment 2 and 10 of plaque purified BTV-10 increased during transmission of the 485 
virus between ruminants and insect vectors, but without changes to the consensus sequence.  486 
Thus, "flat" populations containing a relatively small number of variants appear to be less virulent than 487 
more variable populations.  488 
In addition, our data also suggest that Culicoides cells might function as a natural source of new BTV 489 
variants. BTV is an arbovirus and as such must adapt rapidly to replicate in hosts as different as a warm 490 
blooded mammal and insects. An increased variability of replication in Culicoides cells might allow BTV 491 
to adapt faster to different selective pressures present in the invertebrate and vertebrate hosts. These 492 
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data also reinforce the notion that it is critical to avoid the use of modified live vaccines that induce 493 
even transient viremia in vaccinated animals. The transmission of vaccine strains in the Culicoides 494 
population might then lead to the emergence of “new” strains with the potential to revert to their 495 
original phenotype.   496 
Our study has not taken into consideration factors related to the invertebrate host (e.g. species, sites 497 
and number of “infectious” bites) that could affect BTV pathogenesis. The insect host certainly plays a 498 
role in modulating the interaction between virus and the mammalian host as some studies are 499 
beginning to suggest (86). It is possible that transmission of BTV by different species of Culicoides, in 500 
different geographical areas, could influence the pathogenesis of bluetongue in different ways. This is 501 
an exceedingly important area of research that will need to be addressed in the coming years.  502 
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Figure Legends 747 
 748 
Figure 1. In vitro replication kinetics and pathogenicity in mice of the BTV strains used in this study. 749 
A. Replication kinetics of BTV-2IT2000, BTV-8NET2006 and  BTV-8IT2008 in sheep CPT-Tert cells. Cells were 750 
infected at MOI 0.05, and supernatants were collected 8, 24, 48, 72 and 96 h post infection. 751 
Supernatants were then titrated in BSR cells by limiting dilution assays. Experiments were repeated 752 
independently three times and data are represented as averages of the experiments. Error bars 753 
indicate standard errors. B. Survival plots of 129sv IFNAR−/− mice inoculated intraperitoneally with 300 754 
PFU of BTV-2IT2000, BTV-8NET2006 and BTV-8IT2008. Mice were observed for 2 weeks post inoculation for 755 
the presence of clinical signs of systemic disease. All the viruses used in this study killed all the infected 756 
mice between day 6 and 8 post-inoculation. None of the five mock-infected mice showed any clinical 757 
symptoms (not shown in the figure) and survived throughout the observation period.  758 
Figure 2. Experimental infection of goats and different sheep breeds with BTV-8NET2006. A. Graphs 759 
showing clinical signs recorded in BTV infected goats and various sheep breeds including Sardinian, 760 
mixed breed and Dorset poll (n= 5 per each group). Animal were all of approximately 2 years of age 761 
with the exception of an additional group of 8 months old Dorset poll that are indicated as "Dorset 762 
(young)". Animals were scored daily after infection using a clinical index score (shown in Table S1) 763 
taking into account general symptoms, respiratory signs, fever, need for veterinary intervention or 764 
death. General symptoms included are depression, anorexia, facial and feet lesions. Each group of 5 765 
animals was infected with the same dose of BTV-8NET2006 intradermally. Scores shown for respiratory 766 
symptoms, general symptoms and fever represent the average values collected for each group (± 767 
standard error) during the duration of the entire experiment (28 days). Total scores are instead the 768 
cumulative values for each symptom within a group collected throughout the observation period. B. 769 
Body temperature (average per group; values per each individual animal are shown in Fig. S1) of 770 
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animals infected with BTV-8NET2006. Physiological temperature in sheep ranges normally between 38.3 771 
and 39.9⁰C (black broken lines). Fever in this study was recorded when rectal temperature was above 772 
40⁰C. In experimentally infected animals fever appeared between day 5 and 6 post-infection. C. BTV 773 
RNA in blood samples of experimentally infected sheep and goats. Viral RNA was detected by qRT-PCR 774 
and values are expressed as log10 copy number per μg of total RNA. Note that goats reached the 775 
highest level of BTV RNA in the blood. D. Neutralizing antibodies towards BTV in experimentally 776 
infected animals. Sera were collected at the times indicated following experimental infection (time 0) 777 
and subjected to neutralization assays as indicated in Materials and Methods. Values shown are 778 
averages +/- standard deviations and represent the log10 of the 50% endpoint (proportionate distance, 779 
PD). Mock infected goats and sheep (data shown in Figure S2) did not show any clinical sign of 780 
bluetongue, maintained a physiological temperature throughout the experiment and did not have any 781 
detectable BTV RNA or neutralizing antibodies.  782 
Figure 3. Virulence of BTV-2IT2000, BTV-8NET2006 and BTV-8IT2008. Clinical scores (A), rectal temperature 783 
(B), viremia (C) and neutralizing antibodies (D) of Sardinian sheep (n= 5 per group) infected with either 784 
BTV-2IT2000, BTV-8NET2006 or BTV-8IT2008. Description of graphs in each panel have been described in the 785 
legend of Fig. 2. Note that experimental infections of sheep (Dorset poll, Dorset poll "young", Sardinian 786 
or mixed breed) and goats with BTV-8NET2006 and Sardinian breed sheep with BTV-2IT2000, or BTV-8IT2008 787 
were carried out at the same time but are shown separately in Figures. 2 and 3 to facilitate the 788 
narrative. Consequently, the same sets of data for the Sardinian sheep infected with BTV-8NET2006 are 789 
shown both in Figures 2 and 3. Fever and viremia data for each individual animal are shown in Figure 790 
S3. Note that sheep infected with BTV-8IT2008 display very mild clinical signs, only a transitory fever and 791 
lower levels of viremia compared to sheep infected with BTV-2IT2000 and BTV-8NET2006.  792 
 Figure 4. Genetic differences between BTV-8NET2006 and BTV-8IT2008. Schematic representation of the 793 
10 genomic segments of BTV-8NET2006 and BTV-8IT2008. Mutations in BTV-8IT2008 compared to BTV-794 
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8NET2006 are indicated with red dots. Non-synonymous mutations are highlighted with black asterisks, 795 
and the position of the mutated amino acid residue. Note that the length of the schematic genome 796 
segments and the relative position of synonymous and non-synonymous mutations in the cartoon are 797 
indicative only. 798 
Figure 5. Experimental infection of Sardinian sheep with BTV-8NET2007(blood) and BTV-8NET2007(1KC-2BHK). 799 
Clinical scores (A), rectal temperature (B), viremia (C) and neutralizing antibodies (D) of Sardinian 800 
sheep (n= 5 per group) infected with either BTV-8NET2007(blood) or BTV-8NET2007(1KC-2BHK). Graphs in each 801 
panel have already been described in the legends of Figure 2. Fever and viremia data for each 802 
individual sheep are shown in Figure S4. Note that sheep infected with BTV-8NET2007(blood) displayed 803 
more severe clinical signs, higher levels of fever and viremia compared to sheep infected with BTV-804 
8NET2007(1KC-2BHK). 805 
Fig 6. In vitro adaptation of BTV-8NET2007(blood). The effects of adaptation in vitro of BTV-8NET2007(blood) 806 
was assessed by comparing the genomic sequences of BTV-8NET2007(blood) with the sequences of viruses 807 
isolated in vitro after passaging in Culicoides KC cells (1 passage) and two further passages in BHK21 808 
cells. Schematic representation of the experiment is shown at the top of the figure. Two independent 809 
experiments (represented with blue or red arrows) were carried out and sequences of the viral 810 
genome were obtained after each passage in vitro.  The cartoon shows the schematic representation 811 
of individual genomic segments of BTV. Mutations found in the consensus sequences of the cell 812 
culture passaged viruses are shown as red or blue dots indicating the two independent experiments. 813 
Only two synonymous mutations were selected in Seg-1 and Seg-4 immediately after passage in KC 814 
cells in both independent experiments and were conserved after further passaging in BHK21 cells.   815 
Fig 7. Viral population diversity of BTV-8NET2007(blood) before and after isolation in cell culture. Changes 816 
in nucleotide diversity of BTV-8NET2007(blood)  amplified directly from the spleen of an infected sheep 817 
were compared with sequences of the same virus after isolation in KC and BHK21 cells. Differences 818 
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were assessed by deep sequencing as described in Materials and Methods. Total reads of individual 819 
genome segments were mapped to consensus sequences and single nucleotide polymorphisms (SNPs) 820 
were assigned above the arbitrary 0.1% frequency threshold. On the graph each dot represents the 821 
percentage of nucleotides difference (y-axis) from the consensus sequence of each nucleotide 822 
composing the individual genomic segments of the virus (x-axis). The total number of variable 823 
nucleotides (> 0.1%) for each sample is shown in the right corner of each plot. Dots circled in red in 824 
Seg-1 and Seg-4 of BTV-8NET2007(blood) are those nucleotides that have been selected in the majority of 825 
the viral populations after passage in vitro.  826 
Fig 8. Frequency distribution of variable nucleotide in BTV-8NET2007(blood), BTV-8NET2007(1KC), BTV-827 
8NET2007(1KC-1BHK) and BTV-8NET2007(1KC-2BHK). Histograms showing for each virus the number of nucleotides 828 
with % variation falling within defined borders ("bins"). Panels A-B and C-D represent data of two 829 
independent experiments. Note that panels B and D have a different scale in the y-axis compared to 830 
panels A and C as the frequency of variants present in more than 0.4% of the total population was 831 
significantly lower compared to variants presented in panels A and C.   832 
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